1. 06:00
  2. 07:00
  3. 08:00
  4. 09:00
  5. 10:00
  6. 11:00
  7. 12:00
  8. 13:00
  9. 14:00
  10. 15:00
  11. 16:00
  12. 17:00
  13. 18:00
  14. 19:00
  15. 20:00
  16. 21:00
  1. Plenary Room (Meridian)

  2. Zenit

  3. Nadir

  4. Tycho

  5. Kepler

  6. Catering & Exhibition

    1. 06:00
    2. 07:00
    3. 08:00
    4. 09:00
    5. 10:00
    6. 11:00
    7. 12:00
    8. 13:00
    9. 14:00
    10. 15:00
    11. 16:00
    12. 17:00
    13. 18:00
    14. 19:00
    15. 20:00
    16. 21:00
  1. Plenary Room (Meridian)

    1. Introduction and format of the meeting

      Introduction and format of the meeting

      08:00 - 08:05

    2. Round table discussion - Focal therapy in 2019: Still experimental?

      Focal therapy in 2019: Still experimental? Round table discussion

      08:00 - 08:30

    3. Update on diagnosis and staging

      Update on diagnosis and staging

      08:05 - 08:50

    4. Round table discussion - Novel treatments and decision making in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

      Novel treatments and decision making in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Round table discussion

      08:30 - 09:00

    5. Update on local treatment

      Update on local treatment

      08:50 - 09:25

    6. Take home messages and final remarks

      Take home messages and final remarks

      13:30 - 14:00

  2. Zenit

    1. Case Discussion A2

      • Treatment of oligometastatic disease - Can we define this stage?
      • New trends in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) management - One size fit's all or stratified according to tumour load?
      • What is the optimal first line choice in Castration-Resistant Prostate Cancer (CRPC) treatment?
      • Treatment of recurrent disease after local treatment - The butcher and the baker are selling their wares

      Case discussion 2 Case Discussion A2

      09:00 - 13:30

    2. Case Discussion A1

      • Patient assessment before biopsy: 2019 Update
      • What urologists need to know about radiotherapy
      • Active surveillance: Patient selection and follow-up
      • Technical aspects of open and robotic radial prostatectomy
      • Molecular landscape of prostate cancer
      • Current role of PSMA-PET in upfront staging and recurrent disease

      Case discussion 1 Case Discussion A1

      09:55 - 17:25

  3. Nadir

    1. Case Discussion B2

      • New trends in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) management - One size fit's all or stratified according to tumour load?
      • What is the optimal first line choice in Castration-Resistant Prostate Cancer (CRPC) treatment?
      • Treatment of recurrent disease after local treatment - The butcher and the baker are selling their wares
      • Treatment of oligometastatic disease - Can we define this stage?

      Case discussions 2 Case Discussion B2

      09:00 - 13:30

    2. Case Discussion B1

      • Current role of PSMA-PET in upfront staging and recurrent disease
      • Patient assessment before biopsy: 2019 Update
      • What urologists need to know about radiotherapy
      • Active surveillance: Patient selection and follow-up
      • Technical aspects of open and robotic radial prostatectomy
      • Molecular landscape of prostate cancer

      Case discussion 1 Case Discussion B1

      09:55 - 17:25

  4. Tycho

    1. Case Discussion C2

      • What is the optimal first line choice in Castration-Resistant Prostate Cancer (CRPC) treatment?
      • Treatment of recurrent disease after local treatment - The butcher and the baker are selling their wares
      • Treatment of oligometastatic disease - Can we define this stage?
      • New trends in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) management - One size fit's all or stratified according to tumour load?

      Case discussions 2 Case Discussion C2

      09:00 - 13:30

    2. Case Discussion C1

      • Molecular landscape of prostate cancer
      • Current role of PSMA-PET in upfront staging and recurrent disease
      • Patient assessment before biopsy: 2019 Update
      • What urologists need to know about radiotherapy
      • Active surveillance: Patient selection and follow-up
      • Technical aspects of open and robotic radial prostatectomy

      Case discussion 1 Case Discussion C1

      09:55 - 17:25

  5. Kepler

    1. Case Discussion D2

      • Treatment of recurrent disease after local treatment - The butcher and the baker are selling their wares
      • Treatment of oligometastatic disease - Can we define this stage?
      • New trends in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) management - One size fit's all or stratified according to tumour load?
      • What is the optimal first line choice in Castration-Resistant Prostate Cancer (CRPC) treatment?

      Case discussion 2 Case Discussion D2

      09:00 - 13:30

    2. Case Discussion D1

      • Technical aspects of open and robotic radial prostatectomy
      • Molecular landscape of prostate cancer
      • Current role of PSMA-PET in upfront staging and recurrent disease
      • Patient assessment before biopsy: 2019 Update
      • What urologists need to know about radiotherapy
      • Active surveillance: Patient selection and follow-up

      Case discussion 1 Case Discussion D1

      09:55 - 17:25

  6. Catering & Exhibition

    1. Coffee break

      Coffee break

      09:25 - 09:55

    2. Coffee Break Saturday

      Coffee Break Saturday

      11:00 - 11:30

    3. Lunch Friday

      Lunch Friday

      12:55 - 13:55

    4. Coffee Break Friday

      Coffee Break Friday

      15:55 - 16:25